Only 2 Days Left to Nominate an EPL!

In this ISSUE

Becoming a Pharma Industry Leader

Surfacing Insights: AI and the Physician

The Roots and Rise of Cell and Gene Therapy

Pharm Exec's Emerging Pharma Leaders 2020 — Calling for Nominations

Join us in celebrating and honoring the up-and-coming leaders that are vital to the future of the pharmaceutical and biotech industry. Nominate a colleague or yourself for Pharm Exec's Emerging Pharma Leaders 2020!
... /Read more/

Break Free from Forecast Inaccuracy: How Machine Learning Can Drive Better Quality Commercial Forecasting
Thursday, February 20, 2020 at 11am EST | 8am PST | 4pm GMT | 5pm CET
Register Now

Executive Profile

Jay Galeota: A Better Way to Pharma

Veteran pharma leader Jay Galeota shares learnings and perspectives from an off-the-beaten-path career rise.
... /Read more/

Market Pricing Dynamics for the Machine Learning Age Are You Getting the Insights You Need?
Thursday, March 26, 2019 at 11am EDT |10am CDT |4pm BST |5pm CEST
Register Now

Blog

The Risks and Rewards of Expedited Review

Weighing new strategies to accelerate biomedical product development.
... /Read more/

Calendar

/ 16th Life Sciences Accounting & Reporting Congress — 3/16-3/19 /

/ MASS East Medical Affairs Strategic Summit — 4/14-4/16 /

/ Digital Health for Pharma — 4/20-4/22 /

/ 9th Digital Marketing for Medical Devices West — 4/22-4/24 /

Virtual, Decentralized, Site-less Trials… What Does it All Mean?
Thursday, March 12, 2020 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET
Register Now

The 5 Safes of Risk-Based Anonymization
Wednesday, February 26, 2020 at 10am EST | 9am CST | 3pm GMT | 4pm CET
Register Now

Precision Medicine

Improving the Link from Lab to Physician

How current barriers along the roadway between biomarker testing and drug prescribing can affect decision-making for precision medicines.
... /Read more/

The Current and Future Impact of Artificial Intelligence (AI) on Pharmacovigilance
Tuesday, February 11, 2020 at 11am EST| 8am PST| 4pm GMT| 5pm CET
Register Now

Drug Approvals

505(b)(2): A Pathway to Competitiveness Through Innovation for Specialty and Generic Companies

As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may offer an attractive alternative for companies looking to differentiate their products and diversify their portfolios.
... /Read more/

The Pharm Exec Podcast: Episode 50

Pharma Pricing Climate in Washington

Mike Strazzella, head of federal government relations for Buchanan Ingersoll & Rooney, talks about pricing issues in the pharmaceutical industry, the challenges he encounters, and what he believes needs to change in the industry going forward.
... /Read more/

update my profile / advertise with us / print & digital subscribe / visit pharmexec.com